Myasthenia Gravis approval will boost Soliris revenuesThe FDA has approved Alexion’s Soliris for use in patients with treatment resistant generalised Myasthenia gravis (gMG), making Share XMyasthenia Gravis approval will boost Soliris revenueshttps://pharmaphorum.com/news/myasthenia-gravis-approval-will-boost-soliris-revenues/
